Hyaluronidase (human recombinant)
Hyaluronidase (human recombinant) is an enzyme pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
darzalex faspro | Biologic Licensing Application | 2023-05-26 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
106 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | C90.0 | 5 | 1 | 3 | — | 1 | 9 | |
Non-small-cell lung carcinoma | D002289 | 1 | 1 | 2 | — | — | 4 | ||
Melanoma | D008545 | — | 2 | 2 | — | — | 4 | ||
Primary immunodeficiency diseases | D000081207 | 1 | 2 | 3 | — | — | 4 | ||
Pancreatic ductal carcinoma | D021441 | 1 | — | 1 | — | — | 2 | ||
B-cell lymphoma | D016393 | 1 | — | 1 | — | — | 2 | ||
Smoldering multiple myeloma | D000075122 | — | — | 1 | — | — | 1 | ||
Renal cell carcinoma | D002292 | — | — | 1 | — | — | 1 | ||
Chronic inflammatory demyelinating polyradiculoneuropathy | D020277 | EFO_1000868 | G61.81 | — | — | 1 | — | — | 1 |
Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | C80 | 5 | 3 | — | — | — | 5 | |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 2 | — | — | — | 3 |
Non-hodgkin lymphoma | D008228 | C85.9 | 2 | 1 | — | — | — | 3 | |
Follicular lymphoma | D008224 | C82 | 2 | 2 | — | — | — | 3 | |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 3 | — | — | — | 3 |
Mantle-cell lymphoma | D020522 | C83.1 | — | 2 | — | — | — | 2 | |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 2 | — | — | — | 2 |
Large b-cell lymphoma diffuse | D016403 | C83.3 | 2 | 1 | — | — | — | 2 | |
B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | 2 | — | — | — | 2 | |
Hereditary angioedemas | D054179 | EFO_0004131 | — | 2 | — | — | — | 2 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | — | — | — | 3 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 2 | — | — | — | — | 2 |
Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 | |
Myeloid leukemia | D007951 | C92 | 1 | — | — | — | — | 1 | |
Burkitt lymphoma | D002051 | C83.7 | 1 | — | — | — | — | 1 | |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | — | 1 |
Hypercholesterolemia | D006937 | HP_0003124 | 1 | — | — | — | — | 1 | |
Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infertility | D007246 | EFO_0000545 | — | — | — | — | 1 | 1 | |
Pain management | D059408 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | HYALURONIDASE (HUMAN RECOMBINANT) |
INN | vorhyaluronidase alfa |
Description | Hyaluronidase (human recombinant) is an enzyme pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Enzyme |
Drug class | enzymes |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201718 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 743QUY4VD8 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 0 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
540 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more